Former Bank of Japan official predicts that interest rates may be raised to 0.5% before the end of the year

Masai Takako, a former member of the Bank of Japan’s policy committee, believes that if economic conditions remain broadly unchanged, the Bank of Japan may raise its benchmark interest rate to 0.5% before the end of the year.

Masai Takako, a former member of the Bank of Japan\’s policy committee, believes that if economic conditions remain roughly unchanged, the Bank of Japan may raise its benchmark interest rate to 0.5% before the end of the year.
Masai said in an interview on Monday: It really depends on the real economy. But if the economic expectations remain at the current level, I think it is okay to raise interest rates one or two times. The final increase in interest rates will be around 0.5%.
Masai said that due to rising prices over the past two years, the inflation expectations of businesses and households have changed.
The Bank of Japan wants to make sure everything is normal. But at the same time they have to deal with the side effects, namely a weaker yen, she said.
On the bright side, the company has good performance and has sufficient ability to invest for the future.
She said that the Bank of Japan needs to strengthen communication on the yen issue and remain vigilant about its possible impact on consumption.
Masai served on the Bank of Japan\’s Board of Governors for five years until June 2021.
Data released last Friday showed that Japan\’s inflation cooled for the second consecutive month in April. Consumer prices excluding fresh food rose by 2.2%.
The indicator topped the Bank of Japan\’s 2% price target for the 25th consecutive month.
Masai said that based on recent communications from the Bank of Japan, including summaries of opinions from recent policy meetings and leadership comments, the authorities appear to be focusing on further steepening the government bond yield curve.
She said it was still difficult to judge the Bank of Japan\’s exact assessment of the economic impact of a weak yen.

Like (0)
Previous May 24, 2024 7:42 pm
Next May 27, 2024 4:02 pm

Related posts

  • Sanyou Medical: Loss of 2.0958 million yuan in the first quarter of 2024

    CSI Intelligent Financial Information Sanyou Medical (688085) disclosed its first quarter report for 2024 on April 26. In the first quarter of 2024, the company achieved total operating income of 86.4293 million yuan, a year-on-year decrease of 46.26%; net profit attributable to the parent company was a loss of 2.0958 million yuan, a profit of 34.6535 million yuan in the same period last year; excluding non-net profit loss of 2.9516 million yuan, a profit in the same period last year 30.6539 million yuan; the net cash flow generated from operating activities was -49.5937 million yuan, compared with 40.0311 million yuan in the same period last year; during the reporting period, Sanyou Medical\’s basic earnings per share was -0.01 yuan, and the weighted average return on net assets was -0.11 %.

    stock options April 25, 2024
  • Lingrui Pharmaceutical (600285.SH): Net profit in the first quarter was 190 million yuan, a year-on-year increase of 31.98%

    Gelonghui April 25 | Lingrui Pharmaceutical (600285.SH) announced its first quarter report, with operating income of 909 million yuan, a year-on-year increase of 15.27%, net profit of 190 million yuan, a year-on-year increase of 31.98%, and non-net profit of 181 million yuan. yuan, a year-on-year increase of 31.55%, and basic earnings per share of 0.340 yuan.

    stock options April 25, 2024
  • Glenmark, BeiGene team up to introduce advanced cancer therapies in India; stock trade flat

    Glenmark Pharmaceuticals Ltd.’s subsidiary Glenmark Specialty S.A., entered a marketing and distribution agreement with BeiGene, a global oncology company. This partnership will see Glenmark handle the local development, registration, and distribution of BeiGene’s oncology medicines, Tislelizumab and Zanubrutinib, in India. Tislelizumab, an anti-PD-1 monoclonal antibody, is approved for advanced esophageal squamous cell carcinoma, among other cancers, while Zanubrutinib, a BTK inhibitor, is used for certain hematological malignancies.

    stock options May 22, 2024
  • Gome Communications received advance notice of penalty from the China Securities Regulatory Commission, and investors can now claim compensation

    Injured shareholders can register for the company\’s rights protection on the Sina Shareholder Rights Protection Platform: http://wq.finance.sina.com.cn/ Follow @Sina Securities, follow Sina Brokerage Funds on WeChat, search Sina Shareholder Rights Protection on Baidu, and visit Sina Finance Client You can find us on the homepage of Sina Finance! On the evening of April 15, 2024, Gome Communications (600898) announced that it had received the \”Administrative Penalty and Market Ban Prior Notification\” issued by the China Securities Regulatory Commission. Lawyer Xu Feng from Shanghai Jiucheng Law Firm believed that Gome Communications\’ alleged false statements The illegal facts have been basically clear, and qualified injured investors can initiate claims in accordance with the law. (Column of Lawyer Xu Feng) The above-mentioned announcement information shows that after investigation, the facts that Gome Communications is suspected of violating the law are as follows: 1. Gome Communications’ 2020 annual report contains false records that Gome Communications participated in the Apple scandal carried out by related parties under the control of the same actual controller in 2020 The trading business of mobile phones, Konka color TVs,…

    stock options April 25, 2024
  • Danske Bank says there will be no further interest rate cuts in September after the European Central Bank cut interest rates in June

    Danske Bank no longer forecasts an ECB interest rate cut in September, citing stubborn inflation and a strong start to 2024 for the euro zone economy

    stock options May 24, 2024
  • DuPont plans to split into three companies, CEO Breen will step down

    DuPont plans to spin off into three publicly traded companies, joining a group of industrial conglomerates seeking to boost returns by breaking into smaller, more focused businesses.

    stock options May 23, 2024